Formulation, long-term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa

Cordero-Ramos, J; Merino-Bohórquez, Vicente; Delgado-Valverde, Mercedes; Barros‐Tornay, Rubén; Cameán-Fenández, Manuel; Calleja‐Hernández, Miguel Ángel

doi:10.1136/ejhpharm-2020-002534

Cited by 2 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enrolled patients were instructed to apply 15% resorcinol cream twice a day for 16 weeks as single therapy. The 15% resorcinol formulation used was previously described and its stability was validated 7 …”

Section: Methodsmentioning

confidence: 99%

“…The 15% resorcinol formulation used was previously described and its stability was validated. 7 Age, sex, smoking habit, anatomical location, body mass index (kg/ m 2 ), main comorbidities, and Hurley stage were recorded as demographic and clinical study variables. The number of lesions, nodules, and abscesses, as well as the total number of lesions (including fistula and scars) on the involved and treated regions were recorded.…”

Section: Me Thodsmentioning

confidence: 99%

“…Resorcinol is a phenolic compound with keratolytic, antiseptic, and antipruritic properties 7 . Resorcinol is approved for use in humans in Europe and the United States by the European Medical Agency and the Food and Drugs Administration.…”

Section: Introductionmentioning

confidence: 99%

“…5,6 Resorcinol is a phenolic compound with keratolytic, antiseptic, and antipruritic properties. 7 Resorcinol is approved for use in humans in Europe and the United States by European Medical Agency and the Food and Drugs Administration. The 18th Japanese Pharmacopoeia also contemplates its use in preparations with a concentration of <20%.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness and safety of topical 15% resorcinol in the management of mild‐to‐moderate hidradenitis suppurativa: A cohort study

Cordero-Ramos

Barros‐Tornay

Toledo-Pastrana

et al. 2022

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic autoinflammatory disease of the pilosebaceous follicle with a multifactorial and poorly understood etiopathogenesis. 1 HS entails the development of painful nodules, abscesses, fistulous tracts, and scarring, mainly in the intertriginous areas, which give rise to an unpleasant smelling purulent drainage. HS has been shown to have a significant impact on patient quality of life, 2 and its management requires an individualized and multidisciplinary approach. 3 Although various biologic drugs have emerged to treat HS, antibiotics remain the first-line therapy for patients with HS. 4 Recent

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Me Thodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and safety of topical 15% resorcinol in the management of mild‐to‐moderate hidradenitis suppurativa: A cohort study

Cordero-Ramos

Barros‐Tornay

Toledo-Pastrana

et al. 2022

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment

Zouboulis,

Bechara,

Benhadou

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

IntroductionThis second part of the S2k guidelines is an update of the 2015 S1 European guidelines.ObjectiveThese guidelines aim to provide an accepted decision aid for the selection, implementation and assessment of appropriate and sufficient therapy for patients with hidradenitis suppurativa/acne inversa (HS).MethodsThe chapters have been selected after a Delphi procedure among the experts/authors. Certain passages have been adopted without changes from the previous version. Potential treatment complications are not included, being beyond the scope of these guidelines.ResultsSince the S1 guidelines publication, validation of new therapeutic approaches has almost completely overhauled the knowledge in the field of HS treatment. Inflammatory nodules/abscesses/draining tunnels are the primary lesions, which enable the classification of the disease severity by new validated tools. In relation to the degree of detectable inflammation, HS is classified into the inflammatory and the predominantly non‐inflammatory forms. While the intensity of the inflammatory form can be subdivided by the IHS4 classification in mild, moderate and severe HS and is treated by medication accordingly, the decision on surgical treatment of the predominantly non‐inflammatory form is based on the Hurley stage of the affected localization. The effectiveness of oral tetracyclines as an alternative to the oral combination of clindamycin/rifampicin should be noted. The duration of systemic antibiotic therapy can be shortened by a 5‐day intravenous clindamycin treatment. Adalimumab, secukinumab and bimekizumab subcutaneous administration has been approved by the EMA for the treatment of moderate‐to‐severe HS. Various surgical procedures are available for the predominantly non‐inflammatory form of the disease. The combination of a medical therapy to reduce inflammation with a surgical procedure to remove irreversible tissue damage is currently considered a holistic therapeutic approach.ConclusionsSuitable therapeutic options while considering HS severity in the therapeutic algorithm according to standardized criteria are aimed at ensuring a proper therapy.

show abstract

Formulation, long-term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa

Cited by 2 publications

References 18 publications

Effectiveness and safety of topical 15% resorcinol in the management of mild‐to‐moderate hidradenitis suppurativa: A cohort study

Effectiveness and safety of topical 15% resorcinol in the management of mild‐to‐moderate hidradenitis suppurativa: A cohort study

European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment

Contact Info

Product

Resources

About